Manufacturing excellence alone is no longer enough. The pharma leaders of the next decade will be the ones who built the right regional partnerships when nobody was looking.
For three decades, pharma organised itself around one question. How can we manufacture at scale, efficiently, and competitively? The answer often pointed east, and factories followed. That instinct still exists, but it no longer runs the room. Ask a global manufacturing head what keeps them up at night and cost rarely makes the top five. What comes up instead is fragility, a shipping delay in one port that stalls a launch in twelve markets, a regulator’s decision that strands months of finished product, a shortage of one excipient that shuts a plant.
The industry hasn’t abandoned cost discipline. It has simply recognised that efficiency alone is not a strategy. And it has stopped choosing between countries and started building across them. Nowhere is that shift more visible than in the widening corridor between India and Southeast Asia.
The India side of the story is now backed by numbers most executives underestimate. Pharmaceutical exports reached USD 30.47 billion in 2024-25, up 9.4 percent, with more than 60 percent going to stringent regulatory destinations (Government of India, 2026). The domestic market sits at around USD 60 billion and is expected to roughly double to USD 130 billion by 2030 (PIB, 2025). Underneath that sits an industrial base of more than 3,000 companies, 10,500 manufacturing units, and over 60,000 generic brands. India also supplies 55 to 60 percent of UNICEF’s vaccines and 99 percent of WHO’s DPT vaccine demand (IBEF, 2025).
Southeast Asia is a different story. ASEAN’s roughly 680 million people are aging, urbanising, and buying more medicine every year. IQVIA forecasts sales across 12 key Asian markets to grow at a 3.7 percent CAGR through 2029, backed by a 65-plus population rising from 409 million in 2024 to 514 million in 2029 (IQVIA Market Prognosis, 2025). Put the two profiles side by side and this stops looking like a trade relationship. It starts looking like a corridor. Five shifts explain why.
1. Resilience is now valued at the same level as cost
For twenty years, resilience was something manufacturing heads asked for and CFOs said no to. The pandemic ended that argument. Boards now expect dual sourcing on critical APIs and a qualified second site on anything that matters. The raw materials point is where the corridor thesis gets its sharpest edge. Bain estimates that roughly 72 percent of India’s bulk drug and intermediate imports in FY24 came from China, up from 66 percent in FY22 (Bain & Company, 2025). India’s Production Linked Incentive scheme, with an outlay of Rs 6,940 crore (USD 834 million) through 2029-30, exists precisely to close that dependency (IBEF, 2025).
2. The growth story is regional, not national
The Asia Pacific pharmaceutical market generated USD 355.5 billion in 2025 and is projected to reach USD 611.7 billion by 2033, with India registering the highest country-level growth rate over that stretch (Grand View Research, 2026). Within ASEAN, countries are specialising rather than competing.
Singapore has become the region’s biologics anchor. Output exceeded S$18 billion in 2023, eight of the world’s top ten biopharma companies operate manufacturing sites there, and the country hosts more than 60 biopharma plants (Singapore EDB, 2026). The investment pipeline reads like a global pharma roll call: AstraZeneca committed USD 1.5 billion to an ADC facility, WuXi Biologics USD 1.4 billion to a CRDMO centre, and Pfizer USD 1 billion to small-molecule API capacity (BioSpectrum Asia, 2024).
Thailand is scaling on domestic demand, with the market at around 212 billion baht in 2023 and 6 to 7 percent annual growth forecast through 2027 (Krungsri Research, 2025). Vietnam is upgrading for export, with the market projected to move from USD 6 billion in 2023 to USD 11.6 billion by 2033 and its generics segment growing at the fastest CAGR in ASEAN (B-Company, 2025). Around 159 foreign companies had invested USD 1.8 billion into Vietnamese pharma by 2024. Malaysia is targeting the global halal pharmaceutical market, forecast to exceed USD 130 billion by 2030 (SG Analytics, 2025). Individually none of these is a manufacturing giant. Together they behave like one. The Asia Pacific contract manufacturing market is projected to grow from USD 82.65 billion in 2023 to USD 190.18 billion by 2032 (Credence Research, 2024).
The next competitive advantage in pharmaceutical manufacturing won’t come from building the biggest factory. It will come from building the strongest regional ecosystem around it.
3. Suppliers are turning into partners
Trade policy is one reason procurement teams have to change how they buy. The India-UK Comprehensive Economic and Trade Agreement was signed on 24 July 2025, and the India-EFTA Trade and Economic Partnership Agreement became effective on 1 October 2025, both with binding zero-tariff provisions relevant to Indian generic medicines (PIB, 2025). Zero-tariff access changes what buyers ask their partners to be responsible for. Quality is the other reason. Roughly 89 percent of FDA site inspections in India between 2015 and 2024 resulted in NAI or VAI outcomes, versus 96 to 98 percent in Japan and Europe (Bain & Company, 2025). That gap closes when a global buyer treats its regional partner as a partner and invests in the technology transfer, digitisation, and process discipline that move the number.
4. Capacity is losing ground to capability
You can no longer win on the number of tablets your plant can produce. Everyone has capacity. What separates the interesting companies now is how smart their capacity is. Automation is everywhere. Continuous manufacturing is moving from proof of concept to workhorse. Sustainability has quietly become a real procurement factor. Takeda’s new Singapore facility generates 115 percent of its energy from renewables, and AstraZeneca’s coming ADC site is designed to be zero carbon from day one (Singapore EDB, 2026). Equipment suppliers, cleanroom specialists, automation firms, and process technology partners now sit far closer to manufacturing strategy than they ever have.
5. The most useful conversations have moved
Ten years ago, an executive at a pharma trade show was mostly there to meet existing suppliers. That has changed. The conversations that actually move this industry now happen in rooms where manufacturers, CDMOs, engineering firms, technology providers, regulators, and investors are present at the same time. CPHI South East Asia 2026 is expected to host over 8,000 professionals and more than 400 exhibitors at Bangkok’s Queen Sirikit National Convention Centre from 8 to 10 July, with exhibitors from more than 50 countries (Informa Markets, 2026). Register for free by clicking here: https://inthealthcareweek.com/.
The corridor is not a forecast
Most pieces about Asian pharmaceutical manufacturing end with a prediction. This one does not need to. The corridor between India and Southeast Asia is already happening. You can see it in the plants being built, the partnerships being signed, the trade agreements being ratified, and the engineering money flowing into the region. Companies that treat this as an emerging story are already behind. Companies treating it as the current story are setting the pace. The question left is which organisations show up early enough to shape the decade of manufacturing that gets built next.
By the Numbers
USD 30.47B
Indian pharma exports in FY 2024-25, up 9.4 percent
USD 60B to USD 130B
India’s domestic pharmaceutical market, today to 2030
55 to 60 percent
Share of UNICEF vaccines supplied by India (May 2025)
USD 18B+
Singapore’s biopharmaceutical manufacturing output in 2023
USD 355.5B to USD 611.7B
Asia Pacific pharmaceutical market, 2025 to 2033
8,000+ / 400+ / 50+
Professionals, exhibitors, and countries at CPHI South East Asia 2026
About Hello Pharma
Hello Pharma is a strategic media and intelligence platform focused on the pharmaceutical manufacturing ecosystem. It connects manufacturers, technology providers, engineering companies, and decision-makers across the world’s key pharmaceutical growth corridors.
Sources
Press Information Bureau, Government of India (2025 to 2026). India Brand Equity Foundation (IBEF), Pharmaceutical Exports from India and Indian Pharmaceutical Industry (2025 to 2026). Bain & Company and IBEF, Healing the World: A Roadmap for Making India a Global Pharma Exports Hub. IQVIA Market Prognosis, Key Tailwinds and Headwinds Impacting the Outlook for the Asian Pharmaceutical Market (May 2025). Singapore Economic Development Board, Biopharmaceuticals industry overview (2026). BioSpectrum Asia, How Asia is Emerging as a Biomanufacturing Powerhouse (2024). Grand View Research Horizon Databook, Asia Pacific Pharmaceutical Market (2026). Krungsri Research, Industry Outlook 2025 to 2027: Pharmaceuticals. B-Company, Pharmaceutical Market in Vietnam (2025). SG Analytics, Pharmaceutical Market and Companies in Malaysia (2025). Credence Research, Asia Pacific Contract Pharmaceutical Manufacturing Market (2024). Informa Markets, CPHI South East Asia 2026 event information.
